tetano
Editor, Senior Moderator
BMC Neurol
. 2021 Nov 18;21(1):452.
doi: 10.1186/s12883-021-02489-x.
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
Yamato Nishiguchi[SUP] 1 [/SUP], Hirofumi Matsuyama[SUP] 2 [/SUP], Kuniko Maeda[SUP] 3 [/SUP], Akihiro Shindo[SUP] 2 [/SUP], Hidekazu Tomimoto[SUP] 2 [/SUP]
Affiliations
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. One of the vaccines approved against COVID-19 is the BNT162b2 mRNA COVID-19 vaccine (Pfizer/BioNTech).
Case presentation: We present the case of a 71-year-old man with no history of the SARS-CoV-2 infection or any recent viral or bacterial illnesses who presented with bilateral oculomotor palsy and limb ataxia after BNT162b2 mRNA COVID-19 vaccination. The diagnosis of Miller Fisher syndrome (MFS) was established based on physical examination, brain magnetic resonance imaging (MRI), cerebrospinal fluid analysis (CSF), and positron emission tomography (PET). There was no evidence of other predisposing infectious or autoimmune factors, and the period from COVID-19 vaccination to the appearance of neurological symptoms was similar to that of other vaccines and preceding events, such as infection.
Conclusion: Guillain-Barré syndrome (GBS) and its variants after COVID-19 vaccination are extremely rare. Note that more research is needed to establish an association between MFS and COVID-19 vaccines. In our opinion, the benefits of COVID-19 vaccination largely outweigh its risks.
Keywords: COVID-19; Guillain–Barré syndrome; Miller fisher syndrome; SARS-CoV-2; Vaccination.
. 2021 Nov 18;21(1):452.
doi: 10.1186/s12883-021-02489-x.
Miller Fisher syndrome following BNT162b2 mRNA coronavirus 2019 vaccination
Yamato Nishiguchi[SUP] 1 [/SUP], Hirofumi Matsuyama[SUP] 2 [/SUP], Kuniko Maeda[SUP] 3 [/SUP], Akihiro Shindo[SUP] 2 [/SUP], Hidekazu Tomimoto[SUP] 2 [/SUP]
Affiliations
- PMID: 34789193
- DOI: 10.1186/s12883-021-02489-x
Abstract
Background: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), began in late 2019. One of the vaccines approved against COVID-19 is the BNT162b2 mRNA COVID-19 vaccine (Pfizer/BioNTech).
Case presentation: We present the case of a 71-year-old man with no history of the SARS-CoV-2 infection or any recent viral or bacterial illnesses who presented with bilateral oculomotor palsy and limb ataxia after BNT162b2 mRNA COVID-19 vaccination. The diagnosis of Miller Fisher syndrome (MFS) was established based on physical examination, brain magnetic resonance imaging (MRI), cerebrospinal fluid analysis (CSF), and positron emission tomography (PET). There was no evidence of other predisposing infectious or autoimmune factors, and the period from COVID-19 vaccination to the appearance of neurological symptoms was similar to that of other vaccines and preceding events, such as infection.
Conclusion: Guillain-Barré syndrome (GBS) and its variants after COVID-19 vaccination are extremely rare. Note that more research is needed to establish an association between MFS and COVID-19 vaccines. In our opinion, the benefits of COVID-19 vaccination largely outweigh its risks.
Keywords: COVID-19; Guillain–Barré syndrome; Miller fisher syndrome; SARS-CoV-2; Vaccination.